Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while ...

Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its ...

PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...

Johnson & Johnson continues its $55 billion investment in U.S. operations (first announced back in 2025), targeting ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry ...

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

GSK announced it has entered a multi-year strategic collaboration agreement with Helix aiming to drive the development of ...